Loading people...
Elliott Sigal is a highly respected Board Member at Alnylam Pharmaceuticals, renowned for his extensive background in pharmaceutical research and development, including significant leadership roles such as President, R&D and Chief Scientific Officer at Bristol-Myers Squibb.
As a Board Member, Elliott Sigal's focus is on providing strategic guidance and fostering development within Alnylam Pharmaceuticals. His expertise and strategic interests lie in biotechnology, pharmaceutical R&D, novel drug discovery, and life sciences innovation.
Elliott Sigal currently serves as a Board Member at Alnylam Pharmaceuticals. He previously held prominent leadership positions at Bristol-Myers Squibb and has served on the boards of other leading biotech and pharmaceutical companies.
Elliott Sigal is a Senior Advisor at New Enterprise Associates based in the Greater New York City Area. Prior to joining the firm in 2015, he served as Executive Vice President, Chief Scientific Officer, and President of Research and Development at Bristol-Myers Squibb. During his tenure there, he oversaw the development and commercialization of 14 new medicines, including foundational immuno-oncology therapies such as Yervoy and Opdivo. He previously served as President and Chief Executive Officer of Mercator Genetics and held a board seat at Spark Therapeutics until its $4.3 billion acquisition by Roche in 2019. He holds a medical degree from the University of Chicago and earned a doctorate, master's, and bachelor's degree in industrial engineering from Purdue University. His career focuses on biopharmaceutical innovation, healthcare venture capital, and advancing modern oncology drug discovery.
Elliott Sigal stands as a highly influential figure in the biotechnology and pharmaceutical industries, currently serving as a distinguished Board Member at Alnylam Pharmaceuticals. His role at Alnylam is pivotal, providing strategic oversight and guidance to a company at the forefront of RNA interference (RNAi) therapeutics. Dr. Sigal's deep understanding of drug discovery, clinical development, and regulatory pathways is instrumental in shaping Alnylam's strategic direction and advancing its innovative pipeline of medicines for rare genetic diseases and other conditions.
Before joining Alnylam's board, Dr. Sigal built an illustrious career marked by significant leadership positions. Most notably, he served as President, Research and Development, and Chief Scientific Officer at Bristol-Myers Squibb (BMS) from 2004 to 2013. During his tenure at BMS, he was a driving force behind the transformation of the company's R&D pipeline, overseeing the successful development and launch of several critical new medicines that have positively impacted patient lives globally. His leadership was crucial in fostering a culture of innovation and scientific excellence within one of the world's leading pharmaceutical companies.
Dr. Sigal's investment focus, while primarily through strategic board membership rather than direct venture capital, centers on areas poised for significant medical advancement. These include biotechnology, pharmaceuticals, and the broader life sciences sector, with a particular emphasis on novel therapeutic modalities like gene silencing and gene editing. He is keenly interested in companies that demonstrate strong scientific rigor, a clear path to clinical validation, and the potential to address unmet medical needs. His expertise extends to evaluating early-stage research, navigating complex clinical trials, and understanding the commercialization landscape for innovative drugs.
Beyond Alnylam and BMS, Dr. Sigal's influence is evident through his service on the boards of several other prominent biotech and pharmaceutical companies, including Vertex Pharmaceuticals, Amgen, and Adaptimmune Therapeutics. These roles underscore his broad impact and trusted counsel across the industry. His career began with a strong medical foundation, earning his M.D. from Northwestern University and completing his residency and fellowship training at prestigious institutions like Stanford University and the University of California, San Francisco. This clinical background provides him with a unique patient-centric perspective that informs his strategic decisions in drug development. Elliott Sigal's enduring commitment to scientific innovation and improving global health continues to make him a vital asset to the biopharmaceutical landscape.
